AIER Eye Hospital’s 2025 Performance and Strategic Trajectory

Aier Eye Hospital Group Co., Ltd. (ticker 000000 on the Shenzhen Stock Exchange) delivered a solid 6.53 % increase in revenue for the 2025 fiscal year, a modest rebound compared with the previous year’s contraction. Net profit, however, slipped by 8.88 %, reflecting the company’s aggressive investment in research and digital infrastructure. The firm’s revenue figure for 2025 reached ¥42.20 billion, while its net profit settled at ¥9.07 billion—a 15.03 % YoY gain in absolute terms, but a decline when adjusted for the revenue dip.

Digital Eye‑Care Expansion

Central to Aier’s growth narrative is the acceleration of its “Digital Eye‑Care” platform. The AI‑enabled fundus‑image diagnostic system has surpassed 600,000 calls, and the remote‑diagnosis center has processed more than 8 million remote case reviews. These metrics underscore the company’s transition from a traditional surgical provider to a hybrid model that blends high‑volume clinical service with scalable AI‑driven diagnostics.

The company has also completed an iterative upgrade of the AierGPT ophthalmology vertical large‑language model, a milestone that positions it at the vanguard of AI‑assisted ophthalmic decision‑making. Coupled with the launch of an AI‑based quality‑control system for outpatient records, the firm reports a patient‑satisfaction score of 99.1 %, a benchmark that is rare in the crowded Chinese ophthalmology market.

Organizational Restructuring and Talent Pipeline

In line with its digital ambitions, Aier has restructured its governance. Two new regional management committees—Xiang Gān and Qin Jìn—were established to streamline coordination between the headquarters and provincial branches. The company has also inducted more than 1,200 ophthalmologists and trainee physicians across its network, a move that will sustain service capacity as the demand for myopia‑control and refractive procedures rises.

Aier’s research arm has also expanded: two new specialty groups were formed, and eight national‑level research projects were approved. The firm published 144 peer‑reviewed papers in SCI/Medline venues, reinforcing its position as a knowledge producer in ophthalmology.

Financial Snapshot

  • Market Capitalization: ¥90 billion (≈US$13 billion at 2026 rates)
  • Price‑to‑Earnings Ratio: 27.88
  • 52‑Week High/Low: ¥13.95 / ¥9.32
  • Close (2026‑04‑21): ¥9.86

The firm’s share price has risen 7.40 % on the day it reported, joining a cohort of eye‑care peers such as Prui Eye and Xiang Qi Eye‑Pharma, which experienced double‑digit gains amid a broader sector rally. Aier’s performance is consistent with the industry outlook that projects a continued expansion of the high‑end ophthalmic equipment market beyond ¥200 billion, driven by rising myopia prevalence and a surge in elective refractive surgery.

Forward Outlook

Aier’s strategic thrust toward AI‑enabled diagnostics and remote care is poised to unlock new revenue streams. The company’s already extensive footprint—200 hospitals across 30 provinces, plus branches in Hong Kong and the United States—provides a robust platform for scaling these digital services. The recent introduction of an AI quality‑control module and the high patient‑satisfaction metric suggest a strong foundation for enhancing clinical outcomes while controlling costs.

Given the company’s investment in R&D, the upcoming filing of its 2026 annual report is likely to reveal further capital allocation toward AI platform development, potential cross‑border collaborations, and the expansion of its surgical portfolio into areas such as pediatric ophthalmology and lacrimal disease treatment.

In a market where operational efficiency and technological differentiation are increasingly decisive, Aier’s blend of clinical expertise, AI innovation, and organizational agility positions it well to capture a larger share of China’s burgeoning ophthalmic care market.